Pharmacyte Biotech Inc (OTCMKTS:PMCB) disclosed that the world class team of academics, scientists and physicians that make up the company’s international Diabetes Consortium is finalized with the inclusion of the final two members, Dr. Axel Kornerup Hansen and Dr. Thomas Stratmann.

The details

Dr. Stratmann is an Associate Professor at the University of Barcelona in Spain. He has extensive experience in utilizing a diabetes mouse model of Type I diabetes in which the problem develops rapidly compared to other mouse models. Through the use of the latest model as the Consortium advances in its animal preclinical trials with Cell-in-a-Box-encapsulated Melligen cells, the expert anticipates that the overall advancement period for Pharmacyte Biotech’s diabetes cure will be shortened considerably.

Dr. Kornerup Hansen is a Professor at the University of Copenhagen in Denmark. Pharmacyte stated that he will conduct specially designed preclinical trials to find out the minimum dose of encapsulated Melligen cells needed to control blood glucose levels in diabetic pigs as well as rats, which are a significant model for copying the dosing that will be necessary for human patients.

The rights

Pharmacyte possess the exclusive worldwide rights to utilize the Melligen cells to cure diabetes. They are genetically engineered from “human liver cells.” They have demonstrated to produce insulin in response to the concentration of blood sugar in their environment. The cells were transferred into diabetic mice whose immune response was necessarily not functioning. It normalized the blood glucose levels.

Pharmacyte CEO, Kenneth L. Waggoner stated that they are very pleased as the international Diabetes Consortium is finalized after only a few months of advancement. The academics, physicians and scientists that form consortium are of the highest caliber. In last trading session, the stock price of Pharmacyte declined more than 10% to close the trading session at $0.165. The decline came at a share volume of 4.22 million compared to average volume of 4.72 million.